Immune Phenomena in Autoimmune Skin Disorders

A special issue of Antibodies (ISSN 2073-4468). This special issue belongs to the section "Antibody-Based Therapeutics".

Deadline for manuscript submissions: 20 November 2026 | Viewed by 758

Editors


E-Mail Website
Guest Editor
Autoimmune Blistering Dermatoses Section, Department of Dermatology, Poznan University of Medical Sciences, 49 Przybyszewski Street, 60-355 Poznan, Poland
Interests: pemphigus; pemphigoid; dermatitis herpetiformis; immunofluorescence; IgG4

E-Mail Website
Guest Editor
Department and Division of Practical Cosmetology and Skin Diseases Prophylaxis, Poznan University of Medical Sciences, Collegium Pharmaceuticum, 3 Rokietnicka St., 60-806 Poznan, Poland
Interests: skin immunology; autoimmune blistering diseases; skin barrier; cosmetics; phytotherapy

Special Issue Information

Dear Colleagues,

Autoimmune bullous diseases of the skin and mucous membranes constitute a heterogeneous group of autoimmune mucocutaneous conditions. Pemphigus diseases and pemphigoid diseases are characterized by autoimmunity directed against adhesion molecules, which play a primarily structural role in the mucocutaneous tissues. In dermatitis herpetiformis (DH), enzymes are the target of autoimmunity. An excessive activation of neutrophils is a feature shared by DH and autoinflammatory disorders. The roles of autoantibodies to desmogleins, desmocollins, plakins, BP180, BP230, integrins, p200 (laminin y1 and laminin β4), laminin 332, type VII collagen, epidermal and tissue transglutaminases will be detailed. Antibodies also play a pivotal role in cutaneous pathology in autoimmune connective tissue diseases and vasculitides. Antinuclear antibodies (ANAs) and anti-neutrophil cytoplasmic antibodies (ANCAs) will be discussed. This topic aims to describe recent advances and perspectives on the triggers of autoimmunity, autoantibody turnover and antibody-mediated molecular pathways leading to the clinical manifestations of these diseases. The progress in their diagnosis using imaging techniques and molecular-biochemical methods will be presented. Finally, current and potential treatment regimens aimed at achieving sustained remission of these illnesses will be discussed. Given the immense complexity and extracutaneous pathologies of these conditions, this topic should attract scholars both in fundamental antibody research as well as in clinical research and be of interest to diverse medical community professionals.

Prof. Dr. Marian Dmochowski
Prof. Dr. Justyna Gornowicz-Porowska
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibodies is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pemphigus
  • pemphigoid
  • dermatitis herpetiformis
  • autoimmune connective tissue diseases
  • vasculitides

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

19 pages, 1690 KB  
Article
An Open-Label, Comparative, Parallel Clinical Trial of the Safety, Pharmacokinetics and Immunogenicity of the Ustekinumab Biosimilar GNR-068 and the Originally Developed Ustekinumab as a Reference Drug After a Single Subcutaneous Administration in Healthy Male Volunteers
by Ivan Lyagoskin, Alena Agafonova, Ivan Shevchenko, Nina Akhtyamova-Givirovskaya, Oksana Markova, Marina Pantyushenko, Rakhim Shukurov and Ravil Khamitov
Antibodies 2026, 15(4), 77; https://doi.org/10.3390/antib15040077 - 12 Aug 2026
Viewed by 373
Abstract
GNR-068 is a proposed biosimilar to the ustekinumab reference product (RP), which works through the antagonism of interleukin 12 and interleukin 23. Ustekinumab RP is used for the treatment of chronic inflammatory conditions, including certain forms of plaque psoriasis, psoriatic arthritis, Crohn’s disease, [...] Read more.
GNR-068 is a proposed biosimilar to the ustekinumab reference product (RP), which works through the antagonism of interleukin 12 and interleukin 23. Ustekinumab RP is used for the treatment of chronic inflammatory conditions, including certain forms of plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. Objectives: The purpose of the study is to study the safety, pharmacokinetics, and immunogenicity of the ustekinumab biosimilar GNR-068 and the reference drug Stelara® after a single subcutaneous administration in healthy male volunteers. Methods: This was an open-label, randomized, comparative, parallel-group clinical trial of the safety, pharmacokinetics (PK), and immunogenicity of GNR-068 (JSC GENERIUM) and Stelara® (Manufacturer: Silag AG, Switzerland; RU Holder: JOHNSON & JOHNSON) after a single subcutaneous administration of 45 mg in healthy volunteers. During the trial, 146 volunteers were screened, and 122 were randomized. Results: The results showed that PK similarity was established based on 90% confidence intervals (CIs) for the ratios of geometric means of the primary endpoints of area under the concentration-time curve from time 0 extrapolated to infinity (AUC0–∞) and maximum observed serum concentration (Cmax) being contained within the pre-specified margin of 80.00–125.00%. The incidence of total ADA was lower in the GNR-068 group compared with the reference product group. Adverse events were similar between treatment groups and consistent with the safety profile of the ustekinumab RP. Conclusions: These results indicate that GNR-068 and the ustekinumab RP share similar PK and safety profiles. Full article
(This article belongs to the Special Issue Immune Phenomena in Autoimmune Skin Disorders)
Show Figures

Figure 1

Back to TopTop